Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 100 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $1,952 | -100.0% | 400,000 | 0.0% | 0.11% | -55.7% |
Q3 2022 | $5,768,000 | -4.7% | 400,000 | 0.0% | 0.25% | -23.8% |
Q2 2022 | $6,052,000 | +27.4% | 400,000 | 0.0% | 0.32% | +62.3% |
Q1 2022 | $4,752,000 | -26.7% | 400,000 | 0.0% | 0.20% | +13.1% |
Q4 2021 | $6,484,000 | -43.2% | 400,000 | 0.0% | 0.18% | -31.0% |
Q3 2021 | $11,416,000 | -15.6% | 400,000 | 0.0% | 0.26% | -6.9% |
Q2 2021 | $13,520,000 | +11.8% | 400,000 | 0.0% | 0.27% | +28.0% |
Q1 2021 | $12,096,000 | -14.3% | 400,000 | +40.3% | 0.21% | -29.4% |
Q4 2020 | $14,112,000 | +29.0% | 285,028 | 0.0% | 0.30% | +13.9% |
Q3 2020 | $10,942,000 | -15.6% | 285,028 | -5.0% | 0.27% | -26.7% |
Q2 2020 | $12,961,000 | +24.1% | 300,030 | -25.0% | 0.36% | -17.7% |
Q1 2020 | $10,440,000 | -16.5% | 400,000 | 0.0% | 0.44% | -8.7% |
Q4 2019 | $12,500,000 | +19.9% | 400,000 | 0.0% | 0.48% | +15.6% |
Q3 2019 | $10,424,000 | +13.9% | 400,000 | 0.0% | 0.42% | +13.0% |
Q2 2019 | $9,148,000 | +799.5% | 400,000 | +700.0% | 0.37% | +873.7% |
Q4 2018 | $1,017,000 | -74.5% | 50,000 | -66.7% | 0.04% | -63.5% |
Q3 2018 | $3,984,000 | – | 150,000 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |